Category: patients
-
Why gene therapy for sickle cell is slow to catch on with patients By Reuters
•
Written by Dina Beasley LOS ANGELES (Reuters) – Student Zoe Davis, 20, was just weeks into her first year of school when she returned to the hospital with severe sickle cell pain earlier this month. She does what she can to prevent the bouts of paralysis in her arms, legs…
-
Why gene therapy for sickle cell is slow to catch on with patients By Reuters
•
Written by Dina Beasley LOS ANGELES (Reuters) – Student Zoe Davis, 20, was just weeks into her first year of school when she returned to the hospital with severe sickle cell pain earlier this month. She does what she can to prevent the bouts of paralysis in her arms, legs…
-
Acadia Healthcare is holding patients against their will to increase insurance payouts:NYT
•
Update 6:05 PM ET: Added Acadia Response Acadia Healthcare (NASDAQ:ACHC), one of the largest operators of behavioral health centers in the United States, is holding people against their will in order to maximize insurance payments, The New York Times reported Sunday. In in At least 12 of the 19 states…
-
CALQUENCE ® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
•
First and only BTK inhibitor to demonstrate favorable overall survival trend vs. standard-of-care chemoimmunotherapy in this setting WILMINGTON, Del.–(BUSINESS WIRE)–Positive results from the ECHO Phase III trial showed AstraZeneca (NASDAQ:)’s CALQUENCE ® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival…